Q2 Preview: Eyes on J&J's (JNJ) New CEO Gorsky Into Print, Conference Call

By
A A A
Share |

Johnson & Johnson ( JNJ ) will kick-off the second-quarter earnings season for the Consumer Healthcare sector when it reports on the morning of Tuesday, July 17th. While the stock is outperforming the broader equities market very modestly on Monday (down 0.05 percent versus a 0.14 percent decline in the Dow), shares have risen almost 9 percent over the last month as investors positioned themselves ahead of results, sharply better than a 1.5 percent gain in the DJIA.

Analysts on the Street are currently looking for Johnson & Johnson to post quarterly earnings of $1.29 per share on sales of $16.70 billion. J&J issued EPS of $1.41 on sales of $16.14 billion last quarter (first quarter of 2012), and earnings of $1 per share on sales of $16.6 billion during the second quarter of 2011.

Over the last seven quarters, as shown by our J&J Earnings History page, the company has bested Wall Street's estimates by an average of 2.7 percent.

Analysts are neutral-to-bullish on J&J shares ahead of the quarterly report: our Ratings section shows eight firms with a Buy rating on the stock, eight with a Hold rating, and non suggesting to sell.

Analyst Commentary:

  • Goldman Sachs - The firm is looking for EPS of $1.27 and noted uncertainty related to whether or not the Street's consensus reflects changes in foreign exchange. The firm is expecting sales to be right inline with the consensus.

    Goldman offered the following issues to watch for:
    • New CEO Alex Gorsky's insights into strategy, priorities, and departure if any from predecessors.
    • Color on procedural volumes and MD&D pricing dynamics.
    • Integration of now closed Synthes deal.
    • Commercial outlook for Xarelto given delayed competition from Eliquis, Zytiga post pre-chemo data.
    • Timing and outlook for OTC products returning to the market.
    • Timing of top line data for bapineuzumab.
    Goldman maintains a Neutral rating into the results.
J&J generally reports at 7:45am ET. Stay tuned to our Earnings category to get all the latest news within seconds of the company press release.

Johnson & Johnson will host a conference call at 8:30am ET to review the results. Visit www.investor.jnj.com to join the webcast.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Earnings , Stocks

Referenced Stocks: JNJ

StreetInsider.com

StreetInsider.com

More from StreetInsider.com:

Related Videos

Stocks

Referenced

79%

Most Active by Volume

72,157,294
  • $61.36 ▼ 2.65%
56,535,455
  • $34.92 ▼ 3.78%
49,608,479
  • $4.42 ▼ 3.07%
49,328,445
  • $25.91 ▼ 3.18%
48,932,529
  • $16.37 ▲ 0.49%
38,182,422
  • $3.17 ▼ 1.55%
33,297,581
  • $73.86 ▲ 1.37%
32,790,375
  • $47.43 ▼ 1.02%
As of 4/23/2014, 04:07 PM